Evidence map›Paper›PMID 30385713›Full record

ArticleJCI insight2018

Hemoglobin oxidation-dependent reactions promote interactions with band 3 and oxidative changes in sickle cell-derived microparticles.

Sirsendu Jana, Michael Brad Strader, Fantao Meng, Wayne Hicks, Tigist Kassa, Ivan Tarandovskiy, Silvia De Paoli, Jan Simak, Michael R Heaven, John D Belcher and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Crosstalk Between Sickle Cell Disease and Ferroptosis.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Deciphering mTheranostics · 2024
    Article
  14. Article
  15. Ferroptosis as an emerging target in sickle cell disease.Current research in toxicology · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Sirsendu JanaLaboratory of Biochemistry and Vascular Biology and.
Michael Brad StraderLaboratory of Biochemistry and Vascular Biology and.
Fantao MengLaboratory of Biochemistry and Vascular Biology and.
Wayne HicksLaboratory of Biochemistry and Vascular Biology and.
Tigist KassaLaboratory of Biochemistry and Vascular Biology and.
Ivan TarandovskiyLaboratory of Biochemistry and Vascular Biology and.
Silvia De PaoliLaboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Jan SimakLaboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Michael R HeavenVulcan Analytical LLC, Birmingham, Alabama, USA.
John D BelcherDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Gregory M VercellottiDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Abdu I AlayashLaboratory of Biochemistry and Vascular Biology and.
Center for Vascular Biology Research · USCenter for Biologics Evaluation and Research · USUniversity of Minnesota Medical Center · USVulcan (United States) · US

Funding

Recombinant HbAp Production for In Vivo Toxicity StudiesP01HL110900 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI FRIEDMAN, JOEL M · 2012 to 2016
$10.6M
Heme toxicity and vaso-occlusion in sickle cell diseaseR01HL114567 · NHLBI · UNIVERSITY OF MINNESOTA · PI VERCELLOTTI, GREGORY M · 2012 to 2020
$4.4M
NHLBI NIH HHS P01 HL110900NHLBI NIH HHS R01 HL114567
6 · The paper itself

Abstract

The contribution of intracellular hemoglobin (Hb) oxidation to RBC-derived microparticle (MP) formation is poorly defined in sickle cell disease (SCD). Here we report that sickle Hb (HbS) oxidation, coupled with changes in cytosolic antioxidative proteins, is associated with membrane alterations and MP formation in homozygous Townes-sickle cell (Townes-SS) mice. Photometric and proteomic analyses confirmed the presence of high levels of Hb oxidation intermediates (ferric/ferryl) and consequent β-globin posttranslational modifications, including the irreversible oxidation of βCys93 and the ubiquitination of βLys96 and βLys145. This is the first report to our knowledge to link the UPS (via ubiquitinated Hb and other proteins) to oxidative stress. Ferryl Hb also induced complex formation with band 3 and RBC membrane proteins. Incubation of Townes-SS MPs with human endothelial cells caused greater loss of monolayer integrity, apoptotic activation, heme oxygenase-1 induction, and concomitant bioenergetic imbalance compared with control Townes-AA MPs. MPs obtained from Townes-SS mice treated with hydroxyurea produced fewer posttranslational Hb modifications. In vitro, hydroxyurea reduced the levels of ferryl Hb and shielded its target residue, βCys93, by a process of S-nitrosylation. These mechanistic analyses suggest potential antioxidative therapeutic modalities that may interrupt MP heme-mediated pathophysiology in SCD patients.

Indexed as

Anemia, Sickle CellAnimalsAntisickling AgentsCell-Derived MicroparticlesEndothelial CellsEnergy MetabolismHemoglobinsHemoglobin, SickleHumansHydroxyureaMiceOxidation-ReductionOxidative StressProteomicsAntisickling AgentsHemoglobinsHemoglobin, SickleHydroxyureaCardiovascular diseaseHematologyProteomicsUbiquitin-proteosome systemVascular Biology

Identifiers

PMID30385713
PMCPMC6238743
OpenAlexW2896222092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.